Literature DB >> 3020123

Differential effects of type I IFN and IFN-gamma on the binding of tumor necrosis factor to receptors in two human cell lines.

M Tsujimoto, R Feinman, J Vilcek.   

Abstract

The effect of IFN-alpha and IFN-beta on the expression of cell surface receptors for tumor necrosis factor (TNF) was examined in two human cell lines. In HeLa cells, IFN-alpha and IFN-beta increased 125I-TNF binding, whereas in HT-29 cells these two IFN either slightly decreased or had no effect on 125I-TNF binding. In contrast, IFN-gamma increased 125I-TNF binding in both cell lines. Both IFN-alpha and IFN-beta exerted an antagonistic effect on IFN-gamma-induced stimulation of TNF receptor expression in HT-29 cells, but did not inhibit TNF receptor induction by IFN-gamma in HeLa cells. IFN-gamma and, to a lesser extent, IFN-beta were synergistic with TNF in producing cytotoxic/cytostatic activity in HT-29 cells. Despite the inhibitory effect of IFN-beta on the IFN-gamma-induced stimulation of TNF receptor expression, IFN-beta did not inhibit the synergistic enhancement of TNF cytotoxicity by IFN-gamma in HT-29 cells. The dissociation between the effects of IFN-beta on TNF receptor expression and on the cytotoxic activity of TNF in HT-29 cells suggests that TNF receptor modulation is not a major mechanism of synergism between IFN and TNF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020123

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Interferon receptors.

Authors:  A A Branca
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

Review 2.  Tumor necrosis factor (TNF) alpha: control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition.

Authors:  K Pfizenmaier; M Krönke; P Scheurich; G A Nagel
Journal:  Blut       Date:  1987-07

3.  A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity.

Authors:  A A Creasey; R Yamamoto; C R Vitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  Impaired responsiveness to gamma interferon of macrophages infected with lymphocytic choriomeningitis virus clone 13: susceptibility to histoplasmosis.

Authors:  L Villarete; R de Fries; S Kolhekar; D Howard; R Ahmed; B Wu-Hsieh
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

5.  Role of membrane-associated lymphotoxin (mLT) in the killing activity of lymphokine-activated killer (LAK) cells towards various tumour cell lines.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Hitsumoto; N Takeuchi; S Kimura
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

6.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

7.  Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha.

Authors:  F R Lake; P W Noble; P M Henson; D W Riches
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription.

Authors:  N Nelson; M S Marks; P H Driggers; K Ozato
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

9.  Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.

Authors:  G G Hillman; R K Puri; M A Kukuruga; J E Pontes; G P Haas
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

10.  Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide.

Authors:  Y Noso; J Becker; G Riveau; F Audibert; L Chedid
Journal:  Jpn J Cancer Res       Date:  1990-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.